Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.

MLA

Sallicandro, Luana, et al. “Increased Vasoactive Intestinal Peptide (VIP) in Polycystic Ovary Syndrome Patients Undergoing IVF.” Frontiers in Endocrinology, May 2024, pp. 1–10. EBSCOhost, https://doi.org/10.3389/fendo.2024.1331282.

APA

Sallicandro, L., Gliozheni, E., Feudi, D., Sabbatini, P., Pellegrino, R. M., Alabed, H. B. R., Baldini, D., Gerli, S., Alviggi, C., Cascardi, E., Cicinelli, E., Malvasi, A., & Fioretti, B. (2024). Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF. Frontiers in Endocrinology, 1–10. https://doi.org/10.3389/fendo.2024.1331282

Chicago

Sallicandro, Luana, Elko Gliozheni, Davide Feudi, Paola Sabbatini, Roberto Maria Pellegrino, Husam B. R. Alabed, Domenico Baldini, et al. 2024. “Increased Vasoactive Intestinal Peptide (VIP) in Polycystic Ovary Syndrome Patients Undergoing IVF.” Frontiers in Endocrinology, May, 1–10. doi:10.3389/fendo.2024.1331282.